Perrigo Company plc Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Perrigo Company plc (PRGO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -102.60% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-02-26
- Perrigo Company plc effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -102.60%.
- Perrigo Company plc effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -723.30%.
- Perrigo Company plc effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -42.30%, a 2743.75% decline from fiscal 2021.
- Perrigo Company plc effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was 1.60%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 6 month as first filed | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|---|---|
| 2024-12-31 | -102.60% 10-K · filed 2026-02-26 | |||
| 2023-12-31 | -723.30% 10-K · filed 2026-02-26 | |||
| 2022-12-31 | -42.30% 10-K · filed 2025-02-28 | 42.30% 10-K · filed 2023-02-28 | ||
| 2021-12-31 | 1.60% 10-K · filed 2024-02-27 | -1.60% 10-K · filed 2022-03-01 | ||
| 2020-12-31 | -1624.80% 10-K · filed 2023-02-28 | 70.70% 10-K · filed 2021-03-01 | ||
| 2019-12-31 | -16.50% 10-K · filed 2022-03-01 | -31.20% 10-K · filed 2020-02-27 | ||
| 2018-12-31 | 14.10% 10-K · filed 2021-03-01 | 13.00% 10-K · filed 2019-02-27 | ||
| 2017-12-31 | -61.80% 10-K · filed 2020-02-27 | 63.40% 10-K · filed 2018-03-01 | ||
| 2016-12-31 | -1.30% 10-K · filed 2019-02-27 | -0.70% 10-K · filed 2017-05-22 | ||
| 2015-12-31 | 394.00% 10-K · filed 2018-03-01 | -151.70% 10-KT · filed 2016-02-25 | ||
| 2015-06-27 | 14.70% 10-K · filed 2018-03-01 | 15.50% 10-K · filed 2015-08-13 | ||
| 2014-06-28 | 10.90% 10-K · filed 2017-05-22 | 12.10% 10-K · filed 2014-08-14 | ||
| 2013-06-29 | -0.60% 10-KT · filed 2016-02-25 | |||
| 2012-06-30 | -0.90% 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |